Grufity logoGrufity logo

LLY

368.54USD-0.75(-0.20%)Market Closed

Eli Lilly and Co

Market Summary

USD368.54-0.75Market Closed
-0.20%

LLY Alerts

LLY Stock Price

RSI Chart

Valuation

Market Cap

342.0B

Price/Earnings

60.08

Price/Sales

11.76

Price/Cashflow

48.11

MarketCap/EBT

54.89

Price/Sales

Profitability

EBT Margin

21.43%

Return on Equity

66.61%

Return on Assets

12.09%

Fundamentals

Revenue

Revenue (TTM)

29.2B

Revenue Y/Y

2.49%

Revenue Q/Q

6.99%

Earnings

Earnings (TTM)

6.0B

Earnings Y/Y

30.77%

Earnings Q/Q

52.41%

Price Action

52 Week Range

229.54375.25
(Low)(High)

Last 7 days

1.3%

Last 30 days

3.4%

Last 90 days

18.6%

Trailing 12 Months

51.7%

Financial Health

Current Ratio

1.1

Debt/Equity

0.58

Debt/Cashflow

1.39

Investor Care

Dividend Yield

1.4%

Dividend/Share (TTM)

5.05

Buy Backs (1Y)

0.67%

Diluted EPS (TTM)

6.65

Peers (Alternatives to Eli Lilly and)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
459.8B
96.0B
3.36% 10.92%
24
4.79
5.02% 7.14%
342.0B
29.2B
3.40% 51.66%
60.08
11.76
5.34% 1.02%
266.2B
99.7B
5.27% -0.30%
9.08
2.63
43.92% 53.21%
255.3B
57.2B
9.81% 53.57%
15.4
4.47
35.88% 197.59%
163.4B
46.7B
1.45% 45.00%
24.47
3.5
2.79% 223.53%
MID-CAP
5.5B
4.4B
-19.18% -13.13%
-46.93
1.26
1.80% 57.67%
SMALL-CAP
1.9B
628.4M
6.56% -55.63%
-4.08
3.1
64.35% -18.14%
1.9B
659.0M
4.71% 18.39%
32.36
2.95
16.78% -53.92%
1.5B
-
9.73% -64.43%
-0.54
1.95
-4.11% -144.36%
1.2B
112.7M
-1.62% -29.86%
-10.75
7.76
-54.94% 40.20%
1.1B
3.1M
14.43% -23.02%
-3.57
108.75
-77.09% -12.24%
1.0B
23.5M
5.01% 25.95%
-12.31
166.87
243.57% -1.04%
945.9M
373.2M
1.00% -20.26%
4.56
2.34
-0.39% -38.45%
283.2M
49.7M
-17.14% -53.07%
-8.71
5.67
28.95% 32.80%
68.8M
2.6B
-43.99% -88.43%
-0.03
0.02
-13.88% -4855.92%

Financials for Eli Lilly and

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue0.6%29,24029,07129,32328,31827,759
  S&GA Expenses0.6%6,3896,3536,4146,4326,394
  R&D Expenses1.3%7,1547,0606,9517,0266,892
Earnings Before Taxes5.1%6,5506,2306,7336,1566,785
Net Income6.0%6,0335,6926,1295,5825,972
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets0.8%47,46247,06446,91948,80648,187
  Current Assets3.1%17,64017,11516,96518,45217,808
    Cash Equivalents-0.2%2,6172,6232,4593,8193,788
  Inventory-1.8%3,8313,8993,8933,8863,907
  Net PPE2.0%9,3119,1289,1038,9858,920
  Goodwill0.0%3,8923,8923,8923,8923,884
  Current Liabilities0.2%15,65315,62113,38615,05313,682
    LT Debt, Non Current-3.7%14,14414,69215,15315,34615,522
Shareholder's Equity17.9%10,0708,5459,3318,9797,757
  Retained Earnings17.0%10,0078,5569,3698,9599,639
  Additional Paid-In Capital1.2%6,8296,7466,6566,8336,758
Accumulated Depreciation-0.5%10,07410,12010,1389,9779,963
Shares Outstanding-0.4%900904907--
Minority Interest-16.3%96115131176197
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations7.8%7,6617,1088,0637,2616,919
  Share Based Compensation-1.4%354359358343355
Cashflow From Investing-12.4%-2,780.10-2,473.20-2,492.60-2,762.30-3,057.40
Cashflow From Financing-16.0%-5,791.80-4,991.70-5,951.20-4,131.30-3,896.30
  Dividend Payments3.4%3,4253,3133,1983,0872,984
  Buy Backs0%2,2502,2502,7501,250500

Risks

What is the probability of a big loss on LLY?

14.2%


Probability that Eli Lilly and stock will be more than 20% underwater in next one year

0%


Probability that Eli Lilly and stock will be more than 30% underwater in next one year.

0%


Probability that Eli Lilly and stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does LLY drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Eli Lilly and was unfortunately bought at previous high price.

Returns

Cumulative Returns on LLY

25.2%


10-Year Cumulative Returns

25.7%


7-Year Cumulative Returns

36.4%


5-Year Cumulative Returns

47.9%


3-Year Cumulative Returns

What are the long-term rolling returns for LLY?

FIve years rolling returns for Eli Lilly and.

Which funds bought or sold LLY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
Bridgefront Capital, LLC
NEW
-
201,000
201,000
0.21%
2022-11-29
SALEM CAPITAL MANAGEMENT INC
UNCHANGED
-
-2,000
937,000
0.74%
2022-11-23
Invst, LLC
ADDED
5.15
25,000
238,000
0.04%
2022-11-23
Eagle Bay Advisors LLC
REDUCED
-1.2
-2,694
240,000
0.15%
2022-11-23
Toroso Investments, LLC
ADDED
5.46
281,000
5,716,000
0.24%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
50,145,000
50,145,000
0.59%
2022-11-22
SMITH CHAS P & ASSOCIATES PA CPAS
ADDED
7.65
25,000
364,000
0.03%
2022-11-22
CONTINENTAL INVESTORS SERVICES, INC.
NEW
-
203,000
203,000
0.01%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
58.98
4,249,000
11,508,000
0.35%
2022-11-22
CVA Family Office, LLC
ADDED
2.34
16,000
778,000
0.21%

1–10 of 47

Latest Funds Activity

Are funds buying LLY calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own LLY

Eli Lilly and News

MarketWatch

Pfizer Inc. stock falls Tuesday, underperforms market.10 hours ago

Yahoo Finance

Yahoo Finance

LLY Fair Value

Recent SEC filings of Eli Lilly and

View All Filings
Date Filed Form Type Document
Nov 30, 2022
SC TO-T/A
SC TO-T/A
Nov 28, 2022
SC TO-T/A
SC TO-T/A
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading

Latest Insider Trading transactions for LLY

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-12-01
LILLY ENDOWMENT INC
SOLD
-59,785,500
371.544
-160,911
-
2022-11-21
Kaelin William G Jr
ACQUIRED
179,863
361.17
498
-
2022-11-21
Runge Marschall S
ACQUIRED
179,863
361.17
498
-
2022-11-21
TAI JACKSON P
ACQUIRED
179,863
361.17
498
-
2022-11-21
Hedley Mary Lynne
ACQUIRED
129,660
361.17
359
-
2022-11-21
Alvarez Ralph
ACQUIRED
191,059
361.17
529
-
2022-11-21
LUCIANO JUAN R
ACQUIRED
193,948
361.17
537
-
2022-11-21
Fyrwald J Erik
ACQUIRED
189,614
361.17
525
-
2022-11-21
JACKSON JAMERE
ACQUIRED
179,863
361.17
498
-
2022-11-21
Baicker Katherine
ACQUIRED
179,863
361.17
498
-

1–10 of 50

David A. Ricks
35000
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

LLY Income Statement

2022-09-30
Consolidated Condensed Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Revenue (Note 2)$ 6,941.6$ 6,772.8$ 21,239.6$ 20,318.5
Costs, expenses, and other:    
Cost of sales1,579.11,430.85,081.75,262.6
Research and development1,802.91,705.35,194.95,032.4
Marketing, selling, and administrative1,614.21,577.94,797.24,839.6
Acquired in-process research and development and development milestones (Note 3)62.4177.6668.4532.4
Asset impairment, restructuring, and other special charges (Note 5)206.50.0206.5211.6
Other–net, (income) expense (Note 11)111.0635.9580.9124.3
Costs, expenses, and other5,376.15,527.516,529.616,002.9
Income before income taxes1,565.51,245.34,710.04,315.6
Income taxes (Note 7)113.8135.2402.9460.0
Net income$ 1,451.7$ 1,110.1$ 4,307.1$ 3,855.6
Earnings per share:    
Basic (in dollars per share)$ 1.61$ 1.22$ 4.78$ 4.25
Diluted (in dollars per share)$ 1.61$ 1.22$ 4.76$ 4.23
Shares used in calculation of earnings per share:    
Basic (in shares)900.7906.7901.8907.7
Diluted (in shares)903.8910.8904.5911.7

LLY Balance Sheet

2022-09-30
Consolidated Condensed Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current Assets  
Cash and cash equivalents (Note 6)$ 2,617.4$ 3,818.5
Short-term investments (Note 6)124.790.1
Accounts receivable, net of allowances of $17.7 (2022) and $22.5 (2021)6,715.36,672.8
Other receivables1,609.51,454.4
Inventories3,831.13,886.0
Prepaid expenses and other2,741.92,530.6
Total current assets17,639.918,452.4
Investments (Note 6)2,574.63,212.6
Goodwill3,891.63,892.0
Other intangibles, net7,124.17,691.9
Deferred tax assets2,384.32,489.3
Property and equipment, net of accumulated depreciation of $10,074.0 (2022) and $9,976.7 (2021)9,311.38,985.1
Other noncurrent assets4,535.74,082.7
Total assets47,461.548,806.0
Current Liabilities  
Short-term borrowings and current maturities of long-term debt1,744.61,538.3
Accounts payable1,683.21,670.6
Employee compensation984.1958.1
Sales rebates and discounts8,568.46,845.8
Dividends payable0.0885.5
Income taxes payable685.6126.9
Other current liabilities1,986.93,027.5
Total current liabilities15,652.815,052.7
Other Liabilities  
Long-term debt14,143.815,346.4
Accrued retirement benefits (Note 8)1,832.51,954.1
Long-term income taxes payable3,641.73,920.0
Deferred tax liabilities171.91,733.7
Other noncurrent liabilities1,852.91,644.3
Total other liabilities21,642.824,598.5
Commitments and Contingencies (Note 9)
Eli Lilly and Company Shareholders' Equity  
Common stock594.1596.3
Additional paid-in capital6,829.06,833.4
Retained earnings10,006.58,958.5
Employee benefit trust(3,013.2)(3,013.2)
Accumulated other comprehensive loss (Note 10)(4,295.8)(4,343.1)
Cost of common stock in treasury(50.5)(52.7)
Total Eli Lilly and Company shareholders' equity10,070.18,979.2
Noncontrolling interests95.8175.6
Total equity10,165.99,154.8
Total liabilities and equity$ 47,461.5$ 48,806.0